Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804546 | 0.92 | SMN1; SMN2 (0.90) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL10183423 | 0.87 | SMN1; SMN2 (0.77) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL3081883 | 0.85 | SMN1; SMN2 (0.79) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL4387885 | 0.85 | SMN1; SMN2 (0.90) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL31065708 | 0.85 | SMN1; SMN2 (0.90) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL3088389 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL13504009 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL29944047 | 0.83 | SMN1; SMN2 (0.87) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL3088392 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL2336862 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440417-B2 | Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2286221-A2 | METHODS FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Cayman Chemical Company (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009140364-A2 | METHODS FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, HPGD, GMDS | SMN1; SMN2 3401/4885CA12 4285/4885CA1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.